Skip to content
DraconiticResearch
Search Sources API
186,541 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Histotripsy in tumor therapy: advances in non-thermal mechanical ablation, immune modulation, and clinical translation

  • Yangyang Ma1
  • Xinan Long2
  • Jiangpeng Cheng2
  • Lizhi Niu2
  1. 1Central Laboratory, Guangzhou Fuda Cancer Hospital, Guangzhou, China
  2. 2Department of Oncology, Guangzhou Fuda Cancer Hospital, Guangzhou, China
Read full textPDFDOICite

Abstract

Histotripsy is an emerging non-invasive focused-ultrasound technology that mechanically disrupts tissue through controlled bubble activity rather than sustained thermal coagulation. This review distinguishes shock-scattering cavitational histotripsy, intrinsic threshold histotripsy, and boiling histotripsy and relates their pulse regimes, bubble dynamics, tissue effects, monitoring strategies, and evidence maturity. Mechanical fractionation can expose tumor antigens and damage-associated molecular patterns, but immune outcomes vary by submodality, dose, tumor model, treated fraction, and sampling time; no standardized head-to-head evidence establishes a superior immunological approach. Early prospective liver studies demonstrate high technical feasibility and encouraging local control, whereas post-market cohorts also reveal targeting limitations and uncommon but clinically important vascular, thrombotic, and renal complications. Pancreatic investigation remains ongoing, while the renal CAIN study is completed with registry results and a peer-reviewed first-patient report. A clinically useful dosimetry framework should connect delivered acoustic parameters with in situ cavitation, tissue disruption, imaging or acoustic surrogates, and delayed oncologic and immune endpoints. Histotripsy should currently be viewed as a complementary local therapy with a distinctive mechanical mechanism rather than as a proven replacement for established ablation. Standardized reporting, independently adjudicated safety data, and prospective comparative trials are needed to define its durable oncologic and immunological value.

Related

  1. Structural basis for the CsrA-dependent modulation of translation initiation by an ancient regulatory protein.
    Altegoer F, Rensing Sa, Bange G
    Proceedings of the National Academy of Sciences of the United States of AmericaPeer-reviewedLicence not stated39 citedStructural biologyGeneral biologyHAL
  2. Radiomics- based biomarkers for immunotherapy in non-small cell lung cancer: advances, challenges, and future perspectives in biological interpretation and clinical translation
    Ran Zhang, Xiaoqing Ji, Shuran Yang +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  3. Gene-edited porcine liver xenotransplantation: advances and key clinical translation barriers
    Yao Gao, Min He, Hanfei Huang +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  4. Glaucoma neurodegeneration: targeted modulation of intraocular immune pathways – a review of novel therapeutic advances
    Yunyun Sun, Keyun Xue, Congqin Wen +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMCEurope PMCPMC
  5. Histotripsy-induced vascular remodeling in the tumor microenvironment enhances local and off-target intratumoral drug delivery
    H. Queen, B. Song, H. Kim +10
    bioRxivPreprintCC BYFull textImmunologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{ma2026histotripsy,
  title = {{Histotripsy in tumor therapy: advances in non-thermal mechanical ablation, immune modulation, and clinical translation}},
  author = {Yangyang Ma and Xinan Long and Jiangpeng Cheng and Lizhi Niu},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1858144},
  url = {https://doi.org/10.3389/fimmu.2026.1858144},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Histotripsy in tumor therapy: advances in non-thermal mechanical ablation, immune modulation, and clinical translation
AU  - Yangyang Ma
AU  - Xinan Long
AU  - Jiangpeng Cheng
AU  - Lizhi Niu
PY  - 2026
DA  - 2026/10/12
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1858144
UR  - https://doi.org/10.3389/fimmu.2026.1858144
AB  - Histotripsy is an emerging non-invasive focused-ultrasound technology that mechanically disrupts tissue through controlled bubble activity rather than sustained thermal coagulation. This review distinguishes shock-scattering cavitational histotripsy, intrinsic threshold histotripsy, and boiling histotripsy and relates their pulse regimes, bubble dynamics, tissue effects, monitoring strategies, and evidence maturity. Mechanical fractionation can expose tumor antigens and damage-associated molecular patterns, but immune outcomes vary by submodality, dose, tumor model, treated fraction, and sampling time; no standardized head-to-head evidence establishes a superior immunological approach. Early prospective liver studies demonstrate high technical feasibility and encouraging local control, whereas post-market cohorts also reveal targeting limitations and uncommon but clinically important vascular, thrombotic, and renal complications. Pancreatic investigation remains ongoing, while the renal CAIN study is completed with registry results and a peer-reviewed first-patient report. A clinically useful dosimetry framework should connect delivered acoustic parameters with in situ cavitation, tissue disruption, imaging or acoustic surrogates, and delayed oncologic and immune endpoints. Histotripsy should currently be viewed as a complementary local therapy with a distinctive mechanical mechanism rather than as a proven replacement for established ablation. Standardized reporting, independently adjudicated safety data, and prospective comparative trials are needed to define its durable oncologic and immunological value.
SN  - 1664-3224
ER  -